Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey

M. C. Potenza, K. Peris, E. Berardesca, L. Bianchi, A. Richetta, N. Bernardini, C. De Simone, M. Teoli, A. Zangrilli, S. D'epiro, D. Orsini, A. Narcisi, S. Chimenti, A. Costanzo

Research output: Contribution to journalArticle

Abstract

This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95% CI: 4.2-15.6, p <.001) or infliximab (OR: 6.6; 95% CI: 2.6-16.3, p <.001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95% CI: 1.4-3.8, p = .01) or infliximab (OR: 2.2; 95% CI: 1.1-4.1, p = .018) vs. adalimumab. Adalimumab could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA patients.
Original languageEnglish
Pages (from-to)10.1111/dth.12565. Epub 2017 Dec 7
JournalDermatologic Therapy
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Psoriatic Arthritis
Psoriasis
Italy
Pharmaceutical Preparations
Survival Rate
Surveys and Questionnaires
Multicenter Studies
Adalimumab
Retrospective Studies
Logistic Models
Infliximab
Databases
Survival
Etanercept

Cite this

Potenza, M. C., Peris, K., Berardesca, E., Bianchi, L., Richetta, A., Bernardini, N., ... Costanzo, A. (2018). Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. Dermatologic Therapy, 31(1), 10.1111/dth.12565. Epub 2017 Dec 7. https://doi.org/10.1111/dth.12565 [doi]

Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. / Potenza, M. C.; Peris, K.; Berardesca, E.; Bianchi, L.; Richetta, A.; Bernardini, N.; Simone, C. De; Teoli, M.; Zangrilli, A.; D'epiro, S.; Orsini, D.; Narcisi, A.; Chimenti, S.; Costanzo, A.

In: Dermatologic Therapy, Vol. 31, No. 1, 01.01.2018, p. 10.1111/dth.12565. Epub 2017 Dec 7.

Research output: Contribution to journalArticle

Potenza, MC, Peris, K, Berardesca, E, Bianchi, L, Richetta, A, Bernardini, N, Simone, CD, Teoli, M, Zangrilli, A, D'epiro, S, Orsini, D, Narcisi, A, Chimenti, S & Costanzo, A 2018, 'Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey', Dermatologic Therapy, vol. 31, no. 1, pp. 10.1111/dth.12565. Epub 2017 Dec 7. https://doi.org/10.1111/dth.12565 [doi]
Potenza MC, Peris K, Berardesca E, Bianchi L, Richetta A, Bernardini N et al. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. Dermatologic Therapy. 2018 Jan 1;31(1):10.1111/dth.12565. Epub 2017 Dec 7. https://doi.org/10.1111/dth.12565 [doi]
Potenza, M. C. ; Peris, K. ; Berardesca, E. ; Bianchi, L. ; Richetta, A. ; Bernardini, N. ; Simone, C. De ; Teoli, M. ; Zangrilli, A. ; D'epiro, S. ; Orsini, D. ; Narcisi, A. ; Chimenti, S. ; Costanzo, A. / Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. In: Dermatologic Therapy. 2018 ; Vol. 31, No. 1. pp. 10.1111/dth.12565. Epub 2017 Dec 7.
@article{fe91eb65c5e243bd9e818163c316d9ab,
title = "Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey",
abstract = "This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95{\%} CI: 4.2-15.6, p <.001) or infliximab (OR: 6.6; 95{\%} CI: 2.6-16.3, p <.001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95{\%} CI: 1.4-3.8, p = .01) or infliximab (OR: 2.2; 95{\%} CI: 1.1-4.1, p = .018) vs. adalimumab. Adalimumab could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA patients.",
author = "Potenza, {M. C.} and K. Peris and E. Berardesca and L. Bianchi and A. Richetta and N. Bernardini and Simone, {C. De} and M. Teoli and A. Zangrilli and S. D'epiro and D. Orsini and A. Narcisi and S. Chimenti and A. Costanzo",
note = "LR: 20180924; CI: (c) 2017; JID: 9700070; 0 (Biological Products); 0 (Tumor Necrosis Factor-alpha); B72HH48FLU (Infliximab); FYS6T7F842 (Adalimumab); OP401G7OJC (Etanercept); OTO: NOTNLM; 2017/02/16 00:00 [received]; 2017/05/31 00:00 [revised]; 2017/09/26 00:00 [accepted]; 2017/12/08 06:00 [pubmed]; 2018/09/25 06:00 [medline]; 2017/12/08 06:00 [entrez]; ppublish",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/dth.12565 [doi]",
language = "English",
volume = "31",
pages = "10.1111/dth.12565. Epub 2017 Dec 7",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Blackwell Publishing Inc.",
number = "1",

}

TY - JOUR

T1 - Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey

AU - Potenza, M. C.

AU - Peris, K.

AU - Berardesca, E.

AU - Bianchi, L.

AU - Richetta, A.

AU - Bernardini, N.

AU - Simone, C. De

AU - Teoli, M.

AU - Zangrilli, A.

AU - D'epiro, S.

AU - Orsini, D.

AU - Narcisi, A.

AU - Chimenti, S.

AU - Costanzo, A.

N1 - LR: 20180924; CI: (c) 2017; JID: 9700070; 0 (Biological Products); 0 (Tumor Necrosis Factor-alpha); B72HH48FLU (Infliximab); FYS6T7F842 (Adalimumab); OP401G7OJC (Etanercept); OTO: NOTNLM; 2017/02/16 00:00 [received]; 2017/05/31 00:00 [revised]; 2017/09/26 00:00 [accepted]; 2017/12/08 06:00 [pubmed]; 2018/09/25 06:00 [medline]; 2017/12/08 06:00 [entrez]; ppublish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95% CI: 4.2-15.6, p <.001) or infliximab (OR: 6.6; 95% CI: 2.6-16.3, p <.001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95% CI: 1.4-3.8, p = .01) or infliximab (OR: 2.2; 95% CI: 1.1-4.1, p = .018) vs. adalimumab. Adalimumab could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA patients.

AB - This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95% CI: 4.2-15.6, p <.001) or infliximab (OR: 6.6; 95% CI: 2.6-16.3, p <.001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95% CI: 1.4-3.8, p = .01) or infliximab (OR: 2.2; 95% CI: 1.1-4.1, p = .018) vs. adalimumab. Adalimumab could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA patients.

U2 - 10.1111/dth.12565 [doi]

DO - 10.1111/dth.12565 [doi]

M3 - Article

VL - 31

SP - 10.1111/dth.12565. Epub 2017 Dec 7

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 1

ER -